| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
and
ROBERT B. JAFFE
Reproductive Endocrinology Center, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, California 94143
The structural similarities between human PRL (hPRL) and human GH (hGH) suggest a common evolutionary origin of the two hormones. The existence of these similarities also suggests the existence of a developmental intermediate cell type which has the potential to produce and secrete both hPRL and hGH. We have applied reverse hemolytic plaque assays to monitor the secretions of individual fetal human pituitary cells to determine if any of these cells secrete both hPRL and hGH. When hPRL and hGH assays were performed sequentially on cells obtained from five fetuses of 18–22 weeks gestational age, we consistently found a subpopulation of cells that formed plaques in both assays, i.e. they secreted both hPRL and hGH.
The majority of fetal cells secreting hPRL also secreted hGH at this stage of development. These data were corroborated with light and electron microscopic immunocytochemical localization of hPRL and hGH in a subpopulation of previously identified fetal somatotrophs. These findings suggest that in addition to the classical somatotrophs and lactotrophs, the fetal human pituitary contains an additional cell type which secretes both hPRL and hGH. The dual hormone-secreting cell may represent a common progenitor of these classical cell types. It also may be the cell of origin of those pituitary tumors that secrete both PRL and GH.
* This work was supported in part by Grant HD-08478 (to R.B.J.) and HD-21743 (to J.J.M.).
Present address: Department of Physiology and Biophysics, University of Alabama, Birmingham, Alabama 35294.
To whom all correspondence and requests for reprints should be addressed.
Received April 23, 1987.
This article has been cited by other articles:
![]() |
C Hagen, H D Schroeder, S Hansen, C Hagen, and M Andersen Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy Eur. J. Endocrinol., October 1, 2009; 161(4): 631 - 637. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Fu, S. Nishimura, and T. E Porter Evidence that lactotrophs do not differentiate directly from somatotrophs during chick embryonic development J. Endocrinol., November 1, 2004; 183(2): 417 - 425. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Andersen, C. H. Jensen, R. K. Stoving, J. B. Larsen, H. D. Schroder, B. Teisner, and C. Hagen Fetal Antigen 1 in Healthy Adults and Patients with Pituitary Disease: Relation to Physiological, Pathological, and Pharmacological GH Levels J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5465 - 5470. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yamamuro, T. Aoki, and N. Sensui Effect of Estradiol and FBS on PRL Cells, GH Cells, and PRL/GH Cells in Primary Cultures of Pituitary Cells from Prenatal Rats Experimental Biology and Medicine, February 1, 2001; 226(2): 140 - 143. [Abstract] [Full Text] |
||||
![]() |
I. Pellegrini-Bouiller, C. Manrique, G. Gunz, M. Grino, A. J. Zamora, D. Figarella-Branger, F. Grisoli, P. Jaquet, and A. Enjalbert Expression of the Members of the Ptx Family of Transcription Factors in Human Pituitary Adenomas J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2212 - 2220. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |